1
|
Baron S, Rashal T, Vaisman D, Elhasid R, Shukrun R. Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro. Front Pharmacol 2022; 13:1030991. [PMID: 36506529 PMCID: PMC9730241 DOI: 10.3389/fphar.2022.1030991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 11/14/2022] [Indexed: 11/25/2022] Open
Abstract
Neutrophils are central players in the innate immune system. To protect against invading pathogens, neutrophils can externalize chromatin to create neutrophil extracellular traps (NETs). While NETs are critical to host defense, they also have deleterious effects, and dysregulation of NETs formation has been implicated in autoimmune diseases, atherosclerosis and thrombotic conditions, cancer progression and dissemination, and acute respiratory distress syndrome. Here, we report that selinexor, a first-in-class selective inhibitor of nuclear export approved for the treatment of multiple myeloma and diffuse large B-cell lymphoma, markedly suppressed the release of NETs in vitro. Furthermore, we demonstrate a significant inhibitory effect of selinexor on NETs formation, but not on oxidative burst or enzymatic activities central to NETs release such as neutrophil elastase, myeloperoxidase or peptidyl arginine deiminase type IV. The inhibitory effect of selinexor was demonstrated in neutrophils activated by a variety of NETs-inducers, including PMA, TGF-β, TNF-α and IL-8. Maximal inhibition of NETs formation was observed using TGF-β, for which selinexor inhibited NETs release by 61.6%. These findings pave the way to the potential use of selinexor in an effort to reduce disease burden by inhibition of NETs.
Collapse
Affiliation(s)
- Szilvia Baron
- Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel,*Correspondence: Szilvia Baron,
| | - Tami Rashal
- Karyopharm Therapeutics Inc., Newton, MA, United States
| | - Dmitry Vaisman
- Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel,Department of Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Ronit Elhasid
- Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel,Department of Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Rachel Shukrun
- Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel,Department of Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
| |
Collapse
|
2
|
Moisset P, Vaisman D, Cintolesi A, Urrutia J, Rapaport I, Andrews B, Asenjo J. Continuous modeling of metabolic networks with gene regulation in yeast and in vivo determination of rate parameters. Biotechnol Bioeng 2012; 109:2325-39. [DOI: 10.1002/bit.24503] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Revised: 03/13/2012] [Accepted: 03/14/2012] [Indexed: 11/12/2022]
|
3
|
Abstract
The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potential to considerably enhance the treatment of AMI patients. A number of recent studies have highlighted the potential incremental benefits with adjunctive IIb/IIIa-targeted therapy. In this review, we will discuss the pathophysiology of myocardial infarction (MI), the physiology and role of platelets in thrombosis and describe the currently available drugs. We will briefly summarise the results of recent clinical trials, discuss some key forthcoming trials and attempt to describe how GP IIb/IIIa antagonists may directly impact the immediate and near future day-to-day care of patients with AMI.
Collapse
Affiliation(s)
- J J Ferguson
- Cardiology Research, Mail Code 1-191, St. Luke's Episcopal Hospital, PO Box 20269, Texas Heart Institute, Baylor College of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | | |
Collapse
|
4
|
Vaisman D, Hassan Y, Fred HL. Striking, asymptomatic skin lesions in a 42-year-old man. Hosp Pract (1995) 1998; 33:101-2, 107. [PMID: 9866651 DOI: 10.1080/21548331.1998.11443796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- D Vaisman
- Department of Internal Medicine, University of Texas Health Science Center at Houston, USA
| | | | | |
Collapse
|